Sensus HealthcareSRTS +6.57%76 EBITDA Margin % is -123.75% as of Mar. 2026. GuruFocus rates SRTS with a GF Score™ of 76/100 and a GF Value™ of $2.85 (Fairly Valued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Sensus Healthcare ranks worse than 78.55% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sensus Healthcare's EBITDA for the
three
months ended in Mar. 2026 was $-4.20 Mil. Sensus Healthcare's Revenue for the
three
months ended in Mar. 2026 was $3.39 Mil. Therefore, Sensus Healthcare's EBITDA margin for the quarter that ended in Mar. 2026 was -123.75%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sensus Healthcare EBITDA Margin % Related Terms
Sensus Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sensus Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRTS vs ELUT, COCH, BDMD: EBITDA Margin % Comparison
For the Medical Devices subindustry, Sensus Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sensus Healthcare EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sensus Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sensus Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sensus Healthcare (SRTS) has a EBITDA Margin % of -123.75% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sensus Healthcare and its competitors. According to the industry distribution chart, Sensus Healthcare ranks #641 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 78.6%.
Is Sensus Healthcare's EBITDA Margin % too high?
Sensus Healthcare's current EBITDA Margin % is -123.75%. Based on the distribution chart, Sensus Healthcare ranks #641 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sensus Healthcare has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sensus Healthcare's EBITDA Margin % compare to ELUT and COCH?
According to the Medical Devices & Instruments industry distribution chart, Sensus Healthcare ranks #641 out of 816 companies for EBITDA Margin %. This places Sensus Healthcare in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sensus Healthcare and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sensus Healthcare's current EBITDA Margin % is -123.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensus Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sensus Healthcare (SRTS) is currently considered Fairly Valued. The stock's GF Value™ is $2.85, compared to a current price of $2.92 — trading 2.5% above its estimated fair value. The current EBITDA Margin % is -123.75%. Sensus Healthcare's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sensus Healthcare (SRTS), the current EBITDA Margin % is -123.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sensus Healthcare (SRTS) Overvalued in 2026?
Based on GuruFocus' analysis, Sensus Healthcare stock appears to be overvalued.
The current stock price of $2.92 is trading 2.5% above its estimated GF Value™ of $2.85.
GuruFocus considers Sensus Healthcare to be Fairly Valued.
Key valuation signals for SRTS:
EBITDA Margin %: -123.75%
GF Value™: $2.85 vs. price of $2.92 (2.5% above fair value)
No single metric tells the full story. See the SRTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
76GF Score
Get the complete analysis for SRTS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTS has been successfully added to your 
